No Data
Immuneering to Present Data From Phase 2a Trial of IMM-1-104 in Early January
Express News | Immuneering To Present Phase 2a Trial Data For IMM-1-104 In First-Line And Second-Line Pancreatic Cancer, Along With Phase 1 Data For IMM-6-415, At Virtual Investor Event In January 2025
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5
Morgan Stanley Downgrades Immuneering(IMRX.US) to Sell Rating
No Data
my friend
105751862 : Let's all work hard together and defeat the Short Sellers.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")